Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment to build a specialist cell and gene ...

Detailed price information for Atara Biotherap (ATRA-Q) from The Globe and Mail including charting and trades.

A look at the shareholders of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) can tell us which group is most powerful. With 35% stake, individual investors possess the maximum shares i ...

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable ...

In a large PPMS population that included older patients and people with more advanced disease, ocrelizumab led to a 30% risk ...

Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) ...

Atara Biotherapeutics (ATRA) shares rallied 10% in the last trading session to close at $14.26. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 3, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) submitted a supplemental New Drug ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...

Santa Monica-based Kite, a Gilead company, agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. “In vivo therapy is ...

Iovance secured conditional approval for its cancer drug in Canada. This is pending the outcome of late-stage clinical trials. Just after market close Monday, Iovance announced that its cancer drug ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...